Standout Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
- Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis (2005)
- A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease (2007)
- Inflammation enhances cardiovascular risk and mortality in hemodialysis patients (1999)
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease (2013)
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk (2018)
- Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study (2003)
- Chronic kidney disease (2017)
- Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM) (2013)
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022)
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017)
- Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism (2013)
- KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient (2014)
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials (2018)
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2017)
- Chronic kidney disease and the global public health agenda: an international consensus (2024)
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial (2017)
- Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association (2023)
- A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study (2022)
Immediate Impact
1 from Science/Nature 109 standout
Citing Papers
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
Type 2 diabetes
2022 Standout
Works of Christoph Wanner being referenced
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
2020
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Christoph Wanner | 13557 | 17206 | 11513 | 706 | 44.5k | |
| Mark E. Cooper | 12906 | 17386 | 5789 | 506 | 47.5k | |
| Peter Rossing | 10797 | 22306 | 7288 | 737 | 39.4k | |
| Eberhard Ritz | 19039 | 9208 | 5986 | 926 | 43.6k | |
| Dick de Zeeuw | 19532 | 18996 | 7513 | 818 | 51.7k | |
| George L. Bakris | 11719 | 24604 | 10455 | 836 | 66.0k | |
| Stefan D. Anker | 4086 | 8500 | 7209 | 720 | 54.4k | |
| Kamyar Kalantar‐Zadeh | 29591 | 5515 | 8203 | 905 | 50.2k | |
| James R. Sowers | 3247 | 14251 | 6310 | 681 | 41.2k | |
| William E. Mitch | 11097 | 5887 | 3661 | 298 | 36.5k | |
| Caroline S. Fox | 4251 | 9544 | 5632 | 314 | 35.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...